Table 2 ESI-MS analysis of the tryptic peptides derived from the fused-protein
From: Construction, purification, and characterization of a chimeric TH1 antagonist
# | Peptide sequencea) | m/z exp. | m/z theor. | Zb) | Abs. Errorc) |
|---|---|---|---|---|---|
1 | 11T-K33d) | 908.81 | 908.83 | 3 | 0.02 |
2 | 40M-K44 | 639.34 | 639.35 | 1 | 0.01 |
3 | 45F-K50 | 685.33 | 685.33 | 1 | 0.00 |
4 | 56A-R66f) | 442.87 | 442.88 | 3 | 0.01 |
5 | 67A-K114 | 1781.52 | 1781.54 | 3 | 0.02 |
6 | 101Q-K114d), e) | 807.93 | 807.95 | 2 | 0.02 |
7 | 120N-R151f) | 921.14 | 921.17 | 4 | 0.03 |
8 | 166S-R173 | 506.23 | 506.23 | 2 | 0.00 |
9 | 177I-K181 | 511.31 | 511.28 | 1 | 0.03 |
10 | 190Q-R220f) | 1225.20 | 1225.23 | 3 | 0.03 |
11 | 221V-R227d) | 456.74 | 456.75 | 2 | 0.01 |
12 | 228M-K236d) | 535.24 | 535.25 | 2 | 0.01 |